Results 41 to 50 of about 17,592 (206)

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

ZDHHC17‐Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance

Advanced Science, EarlyView.
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang, Peipei Song, Xueji Wu, Lei Wang, Wei Xie, Pinning Feng, Chao Cheng, Jianping Guo   +7 more
wiley   +1 more source

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer [PDF]

, 2022
BackgroundFor estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combination with a cyclin-dependent kinase
Cohen, Patrick, Delaloge, Suzette, Pelekanou, Vasiliki, Iwata, Hiroji, Kanagavel, Dheepak, Cartot-Cotton, Sylvaine, Bardia, Aditya, Cortes, Javier, Shao, Zhi-Ming, O’Shaughnessy, Joyce, Hurvitz, Sara A, Liu, Qianying   +11 more
core   +1 more source

Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval

Breast Cancer Research, 2018
Background Rapidly evolving understanding of cancer biology has presented novel opportunities to translate that understanding into clinically relevant therapy.
J. K. Kish, M. A. Ward, D. Garofalo, H. V. Ahmed, L. McRoy, J. Laney, G. Zanotti, J. Braverman, H. Yu, B. A. Feinberg   +9 more
doaj   +1 more source

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

BMC Cancer, 2022
Introduction Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms.
Kadir Eser, Arif Hakan Önder, Emel Sezer, Timuçin Çil, Ali İnal, Banu Öztürk, Vehbi Erçolak, Berna Bozkurt Duman, Halil Çelik, Tolga Köşeci, Oğuzhan Kesen   +10 more
doaj   +1 more source

Topology‐Aware Deep Learning on Higher‐Order Structures for Drug Response Prediction

Advanced Science, EarlyView.
We present TopDr, a topology‐aware deep learning framework that encodes both drugs and cell lines as multiscale simplicial complexes, capturing interactions at the 0‐, 1‐, and 2‐simplex levels. By jointly integrating local higher‐order neighborhoods and global topological structures, TopDr generates enriched representations for sensitivity prediction ...
Cong Shen, Guancen Lin, Chuan‐Shen Hu, Yong Wang   +3 more
wiley   +1 more source

Verapamil as a culprit of palbociclib toxicity

, 2018
A promising drug, palbociclib, received accelerated approval as a first line treatment when used with the aromatase inhibitor, letrozole, for postmenopausal women with hormone receptor positive advanced or metastatic breast cancer. We report a case of a
Jon D Herrington, Jasmine L Gowarty
core   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, EarlyView.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

Frontiers in Pharmacology, 2023
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor (
Claudia Arndt, Claudia Arndt, Antje Tunger, Antje Tunger, Rebekka Wehner, Rebekka Wehner, Rebekka Wehner, Rebecca Rothe, Rebecca Rothe, Eleni Kourtellari, Stephanie Luttosch, Katharina Hannemann, Stefanie Koristka, Liliana R. Loureiro, Anja Feldmann, Torsten Tonn, Torsten Tonn, Torsten Tonn, Theresa Link, Theresa Link, Theresa Link, Jan Dominik Kuhlmann, Jan Dominik Kuhlmann, Jan Dominik Kuhlmann, Pauline Wimberger, Pauline Wimberger, Pauline Wimberger, Michael Philipp Bachmann, Michael Philipp Bachmann, Michael Philipp Bachmann, Michael Philipp Bachmann, Marc Schmitz, Marc Schmitz, Marc Schmitz   +33 more
doaj   +1 more source

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies

Advanced Science, EarlyView.
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen   +4 more
wiley   +1 more source